News

InSphero and Hesperos Announce Strategic Collaboration to Offer End-to-End Solutions in Drug Discovery and Toxicology

News 06.06.2025 InSphero, the global leader in industry-ready 3D in vitro solutions for preclinical research, announced a new collaborative partnership with Hesperos, uniting two leading innovators in the field of advanced in vitro and microphysiological (MPS) systems. This partnership will provide pharmaceutical and biotechnology companies with bespoke, integrated solutions spanning the entire drug development pipeline from early-stage screening...

read more

InSphero Expands 3D Microtissue Portfolio Through Strategic Agreement with Tessara Therapeutics

News 06.06.2025 InSphero, the global leader in scalable and reliable 3D in vitro cell culture solutions for drug discovery, has entered into a distribution agreement with Tessara Therapeutics, an Australian biotech company known for its advanced neuronal microtissue technology. This agreement further strengthens our portfolio of physiologically relevant 3D models and enables us to offer best-in-class neuronal...

read more

Biognosys Launches Spectronaut 20 and SpectroMine 5, Setting New Benchmarks in Immunopeptidomics

News 03.06.2025 May 30th, 2025 – ZUERICH, Switzerland and BOSTON, Massachusetts, US. – GlobeNewswire – Biognosys, a global leader in mass spectrometry-based proteomics solutions, announces the launch of Spectronaut® 20 and SpectroMine™ 5 at the ASMS 2025 Annual Conference, taking place June 1–5 in Baltimore, MD. These major software updates mark significant technological advances in unspecific search performance, immunopeptidomics, and cloud-ready proteomics workflows. At...

read more

Araris, Novago and Tolremo are nominated for Strüngmann Award

News 02.06.2025 Au, Schlieren, and Basel, Switzerland — A Swiss company will receive the Strüngmann Award for revolutionary technologies in the life science sector in the DACH region in 2025. The nominees are Araris in Au, NovaGo in Schlieren, and Tolremo in Basel. Three companies from Switzerland have been nominated for the Strüngmann...

read more

Positive Phase 2 trial interim analysis on safety and efficacy for denovoSkin™ in pediatric burn patients

News 28.05.2025 CUTISS has completed an interim analysis in its Phase 2 clinical trial evaluating the safety and efficacy of denovoSkin™ in children with severe burns, with positive results. The randomized, controlled trial enrolled 12 pediatric patients, comparing denovoSkin™ to the current standard of care (autografting) using an intra-patient control design. The results from...

read more